The Silicon Review
Incyte is a company founded on the premise that investment in good science and the rigorous pursuit of R&D excellence can translate into new medicines that can positively affect patients’ lives. Its goal is to become a leading global biopharmaceutical company.
Its therapeutic focus is primarily oncology. It believes the future of cancer treatment lies with immune therapies, which seek to recruit the patient’s own immune system to tackle cancer, and with targeted therapies, which aim to block the effects of cancer-causing mutations. In addition to Incyte’s marketed products, it has a broad and diversified selection of clinical candidates in its growing portfolio, from both its own laboratories and from partners via licensing transactions.
Founded in 2002, Incyte Corporation’s global headquarters are located in Wilmington, DE, and today, the company employs more than 1,200 people in the US, Europe, and Japan.
“We have an experienced team with a track record of success, and our goal is to create first-in-class and best-in-class therapeutics,” says Hervé Hoppenot, Chairman, President and CEO of Incyte “We pursue this by combining critical target selection with our world-class biology and chemistry expertise.”
Science and Innovation
Our world-class expertise, investment in sound and precise science, and our rigorous pursuit of R&D excellence drive our efforts to identify new molecules with the potential to improve the lives of patients, make a difference in healthcare, and build sustainable value for all our stakeholders.
We are committed to positively impacting the lives of patients with cancer and other diseases. Our clinical research is held to the highest standards of scientific and ethical rigor, and we strive to implement programs and initiatives to support patients through their treatment journeys and to remove barriers to access for our medicines.
Compliance and Transparency
We aim to make a difference—for patients, medical professionals, organizations, the broader healthcare community, and all our global stakeholders. To achieve these goals, we are committed to conducting business ethically. We hold ourselves accountable to the highest standards to ensure that all of our interactions are conducted appropriately. We regularly review and amend our practices according to our own standards, as well as the standards required of us by the communities in which we live and work.
The Global Community
We exist to improve the lives of people facing life-altering and life-threatening diseases like cancer, and we actively support various local and global initiatives that are health-related or benefit the communities in which we live and work. We strive to comply with all laws and regulations that govern environmental, health, and safety matters and to adhere to sustainable business practices.
What Incyte Does
Drug Discovery and Development
At Incyte, its therapeutic focus is primarily oncology. Since the company began its drug discovery and development activities in early 2002, it has filed Investigational New Drug (IND) applications and progressed multiple internally developed proprietary compounds into clinical development. In late 2011, Incyte received its first US Food and Drug Administration approval for Jakafi (ruxolitinib), a JAK1 and JAK2 inhibitor.
Incyte has an exceptional team of drug discovery and development scientists, led by distinguished executives with proven records of success and many scientific and clinical achievements. It employs only the best and those who adhere to the highest standards of scientific and clinical rigor, and it resources its programs for success. Incyte has a strong discovery team that is tightly integrated with all disciplines, including development, regulatory, and commercial operations.
Incyte’s scientific innovation is based on a proven competency in medicinal chemistry, which is seamlessly integrated into a discovery process that is tailored to individual program needs. It has expanded its drug identification efforts to include large molecules, which enables the company to access a broad range of cancer drug targets. Incyte continually modifies the resourcing of its discovery efforts to maximize information content when and where Incyte need it and ensure that each program, regardless of stage, is executed in the most efficient and data-rich manner possible.
Greet the Chief
Hervé Hoppenot, Chairman, President, and Chief Executive Officer: Hervé Hoppenot joined Incyte in 2014 as President and Chief Executive Officer and was appointed Chairman of the Board of Directors in 2015. Prior to joining Incyte, Mr. Hoppenot was the President of Novartis Oncology, where he was responsible for translational medicine, development, approval, and commercialization, which included $11 billion in global sales, the largest oncology pipeline in the industry, and 8000 employees in 50 countries. Mr. Hoppenot joined Novartis in 2003, and, in addition to his role as President, served as Chief Commercial Officer, Head of Global Product Strategy & Scientific Development, and Senior Vice President, Head of Global Marketing. He started his career in 1983 with Rhone Poulenc, later known as Aventis, where he served in several senior roles of increasing responsibility, including Vice President of Oncology and Head of the US Oncology business unit.
Mr. Hoppenot holds a diploma from ESSEC Business School.